AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ZIDOVUDINE+ LAMIVUDINE

9 registrations across 3 African markets— 6 active

Markets with ZIDOVUDINE+ LAMIVUDINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
ZIDOVUDINE+LAMIVUDINE 300MG/150MG TABLET
TABLET
🇲🇼MalawiexpiredMar 2024
ASPEN-LAMZID COMBINATION PRODUCT TABLET
TABLET
🇲🇼MalawiexpiredJun 2014
ZIDOLAM COMBINATION PRODUCT TABLET
TABLET
🇲🇼MalawiexpiredJun 2012
ZIDOVUDINE+ LAMIVUDINE
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaCIPLA LTD.active
ZIDOVUDINE+ LAMIVUDINE
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaCIPLA LTD.active
Avocomb
Tablets
🇹🇿TanzaniaSun Pharmaceutical Industries Ltdactive
ZIDOVUDINE+ LAMIVUDINE
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaCIPLA LTD.active
Lamivudine and Zidovudine
Tablets
🇹🇿TanzaniaMylan Laboratories Limitedactive
ZIDOVUDINE+ LAMIVUDINE
ORAL SOLID ORDINARY TABLETS
🇺🇬UgandaCIPLA LTD.active

ZIDOVUDINE+ LAMIVUDINE in Africa — Regulatory Overview

ZIDOVUDINE+ LAMIVUDINE is registered across 3 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Uganda, Malawi, Tanzania. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 6 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.